Raymond James & Associates’s Idexx Laboratories IDXX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $29M | Sell |
57,383
-22,023
| -28% | -$10.7M | 0.02% | 639 |
|
|
2024
Q2 | $38.7M | Buy |
79,406
+5,072
| +7% | +$2.55M | 0.03% | 493 |
|
|
2024
Q1 | $40.1M | Buy |
74,334
+1,399
| +2% | +$765K | 0.03% | 479 |
|
|
2023
Q4 | $40.5M | Sell |
72,935
-25,059
| -26% | -$11.8M | 0.03% | 458 |
|
|
2023
Q3 | $42.8M | Buy |
97,994
+24,147
| +33% | +$12M | 0.04% | 394 |
|
|
2023
Q2 | $37.1M | Sell |
73,847
-3,429
| -4% | -$1.64M | 0.03% | 455 |
|
|
2023
Q1 | $38.6M | Buy |
77,276
+10,525
| +16% | +$5.04M | 0.03% | 425 |
|
|
2022
Q4 | $27.2M | Sell |
66,751
-1,347
| -2% | -$523K | 0.03% | 540 |
|
|
2022
Q3 | $22.2M | Sell |
68,098
-4,778
| -7% | -$1.76M | 0.02% | 581 |
|
|
2022
Q2 | $25.6M | Sell |
72,876
-7,627
| -9% | -$3.11M | 0.03% | 520 |
|
|
2022
Q1 | $44M | Buy |
80,503
+3,345
| +4% | +$1.76M | 0.04% | 396 |
|
|
2021
Q4 | $50.8M | Buy |
77,158
+2,354
| +3% | +$1.48M | 0.04% | 376 |
|
|
2021
Q3 | $46.5M | Buy |
74,804
+1,847
| +3% | +$1.24M | 0.04% | 379 |
|
|
2021
Q2 | $46.1M | Buy |
72,957
+5,525
| +8% | +$3.05M | 0.04% | 371 |
|
|
2021
Q1 | $33M | Buy |
67,432
+5,351
| +9% | +$2.68M | 0.03% | 449 |
|
|
2020
Q4 | $31M | Buy |
62,081
+13,229
| +27% | +$5.92M | 0.03% | 441 |
|
|
2020
Q3 | $19.2M | Buy |
48,852
+10,158
| +26% | +$3.76M | 0.02% | 556 |
|
|
2020
Q2 | $12.8M | Buy |
38,694
+1,594
| +4% | +$462K | 0.02% | 703 |
|
|
2020
Q1 | $8.99M | Sell |
37,100
-1,050
| -3% | -$274K | 0.01% | 788 |
|
|
2019
Q4 | $9.96M | Sell |
38,150
-4,154
| -10% | -$1.09M | 0.01% | 904 |
|
|
2019
Q3 | $11.5M | Sell |
42,304
-407
| -1% | -$113K | 0.02% | 794 |
|
|
2019
Q2 | $11.8M | Buy |
42,711
+8,692
| +26% | +$2.14M | 0.02% | 773 |
|
|
2019
Q1 | $7.61M | Sell |
34,019
-6,970
| -17% | -$1.44M | 0.01% | 967 |
|
|
2018
Q4 | $7.63M | Buy |
40,989
+8,911
| +28% | +$1.83M | 0.01% | 887 |
|
|
2018
Q3 | $8.01M | Buy |
32,078
+7,326
| +30% | +$1.78M | 0.01% | 954 |
|
|
2018
Q2 | $5.39M | Sell |
24,752
-1,693
| -6% | -$349K | 0.01% | 1151 |
|
|
2018
Q1 | $5.06M | Buy |
26,445
+878
| +3% | +$162K | 0.01% | 1152 |
|
|
2017
Q4 | $4M | Sell |
25,567
-15,014
| -37% | -$2.36M | 0.01% | 1250 |
|
|
2017
Q3 | $6.31M | Sell |
40,581
-4,963
| -11% | -$785K | 0.01% | 967 |
|
|
2017
Q2 | $7.35M | Buy |
45,544
+7,139
| +19% | +$1.16M | 0.02% | 865 |
|
|
2017
Q1 | $5.94M | Buy |
38,405
+2,337
| +6% | +$322K | 0.01% | 932 |
|
|
2016
Q4 | $4.23M | Buy |
36,068
+5,421
| +18% | +$619K | 0.01% | 1073 |
|
|
2016
Q3 | $3.46M | Sell |
30,647
-62,504
| -67% | -$6.59M | 0.01% | 1133 |
|
|
2016
Q2 | $8.65M | Sell |
93,151
-23,742
| -20% | -$2.04M | 0.03% | 601 |
|
|
2016
Q1 | $9.15M | Buy |
116,893
+8,361
| +8% | +$602K | 0.03% | 556 |
|
|
2015
Q4 | $7.91M | Sell |
108,532
-721
| -0.7% | -$51.4K | 0.03% | 616 |
|
|
2015
Q3 | $8.11M | Buy |
109,253
+10,474
| +11% | +$750K | 0.03% | 562 |
|
|
2015
Q2 | $6.34M | Buy |
98,779
+43,035
| +77% | +$2.98M | 0.02% | 703 |
|
|
2015
Q1 | $4.31M | Buy |
+55,744
| New | +$4.34M | 0.02% | 824 |
|
Other funds holding IDXX
Raymond James & Associates's IDXX Position: Q3 2024 in Review
Raymond James & Associates reduced its Idexx Laboratories (IDXX) stake by 28% in Q3 2024, selling an estimated $10.7M and leaving 57,383 shares worth $29M. The position accounts for 0.02% of the portfolio, ranked #639.
Raymond James & Associates first reported a position in IDXX in Q1 2015 and has held it in 39 quarters since. The position peaked at $50.8M in Q4 2021. 1,116 funds tracked by Wall St. Rank hold IDXX as of Q3 2024.
- Raymond James & Associates held 57,383 shares of Idexx Laboratories worth $29M as of Q3 2024.
- Raymond James & Associates sold 22,023 Idexx Laboratories shares in Q3 2024, an estimated $10.7M.
- Idexx Laboratories made up 0.02% of Raymond James & Associates's portfolio in Q3 2024, its #639 holding.
- Raymond James & Associates first reported a position in Idexx Laboratories in Q1 2015 and has held it in 39 quarters since.
- Raymond James & Associates's Idexx Laboratories position peaked at $50.8M in Q4 2021.
- 1,116 funds tracked by Wall St. Rank held Idexx Laboratories as of Q3 2024.
Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.